"Everyone knows that this is a sale of DNA to a third party," California's attorney Bernard Eskandari said in court. "It has always been a sale of DNA to a third party." TTAM Research won a bankruptcy auction for 23andMe's assets in June, overbidding a $265 million offer from Regeneron Pharmaceuticals. TTAM said it would continue to protect customers' genetic data and maintain 23andMe's privacy policies, including customers' right to delete their data. Wojcicki was 23andMe's CEO before its bankruptcy filing, and her new nonprofit's name is an acronym formed from the first letters of the words "twenty-three and me." Several other U.S. states, including New York and Texas, also opposed the sale and said that their state laws also prevent the sale of customers' genetic data without their consent. Walsh overruled those objections on June 27. (Reporting by Dietrich Knauth in New York, Editing by Alexia Garamfalvi and Marguerita Choy)